BIOMAT Database Logo BIOMAT Database Logo

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. 1996

L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

The safety, tolerability, pharmacokinetic profile, and preliminary activity of lamivudine (2'-deoxy-3'-thiacytidine), a novel cytidine nucleoside analogue with antiretroviral activity, in human immunodeficiency virus (HIV)-infected children beyond the neonatal period were studied. Ninety children received dosages of 1-20 mg/kg/day. Pharmacokinetic evaluation demonstrated serum and cerebrospinal fluid concentrations that increased proportionally to dose. As of January 1994, 11 children had been withdrawn from study for disease progression and 10 because of possible lamivudine-related toxicity, and 6 had died. CD4 and CD8 cell counts remained stable over 24 weeks in therapy-naive children and decrease slightly in previously treated children. Quantitative immune complex-dissociated p24 antigen and HIV RNA were decreased significantly at 12 and 24 weeks. In vitro resistance to lamivudine was documented in sequential virus isolates from some patients by 12 weeks. Lamivudine was well-tolerated and exhibited virologic activity in children, although future use in children is likely to be in combination antiretroviral regimens.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010195 Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis. Acute Edematous Pancreatitis,Acute Pancreatitis,Pancreatic Parenchyma with Edema,Pancreatic Parenchymal Edema,Pancreatitis, Acute,Pancreatitis, Acute Edematous,Peripancreatic Fat Necrosis,Acute Edematous Pancreatitides,Acute Pancreatitides,Edema, Pancreatic Parenchymal,Edematous Pancreatitides, Acute,Edematous Pancreatitis, Acute,Fat Necrosis, Peripancreatic,Necrosis, Peripancreatic Fat,Pancreatic Parenchymal Edemas,Pancreatitides, Acute,Pancreatitides, Acute Edematous,Parenchymal Edema, Pancreatic,Peripancreatic Fat Necroses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
June 1995, The Journal of infectious diseases,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.
March 1998, Pediatrics,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
August 1995, Pediatrics,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Sepsis in children with human immunodeficiency virus infection. The Madrid HIV Pediatric Infection Collaborative Study Group.
June 1995, The Pediatric infectious disease journal,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
February 1998, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute.
May 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
October 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
May 1995, The Journal of infectious diseases,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
April 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
L L Lewis, and D Venzon, and J Church, and M Farley, and S Wheeler, and A Keller, and M Rubin, and G Yuen, and B Mueller, and M Sloas, and L Wood, and F Balis, and G M Shearer, and P Brouwers, and J Goldsmith, and P A Pizzo
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
April 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!